Proprotein convertase subtilisin/kexin type 9 (PCSK9) can impair the ability of the liver to process low-density lipoprotein cholesterol (LDL-C) in the blood by binding to low-density lipoprotein receptors (LDL-R) and interfering with their recycling, leading to cholesterol buildup in the blood and eventually cardiovascular diseases. This evidence concerns the gene PCSK9 and cardiovascular disorder.